Author: Fred Gardner

Protected: THCA is virtually impotent at the cannabinoid receptors

The Cannabis plant produces cannabinoids in their acidic form —as anyone who has tasted a freshly pruned bud can attest. In recent years, doctors and patients have become very interested in THC Acid, which is said to be non-psychoactive while exerting anti-seizure effects and other medical benefits. Two isomers of THC Acid  have been identified —THCA-A and THCA-B. “Cannabis primarily biosynthesizes THCA-A, and this isomer has been the focus of most pharmacological studies,” Dr. John McPartland and pharmacologists from New Zealand note in a paper published in Cannabis and Cannabinoid Research. “Conversely, THCA-B has greater stability and crystalizes more readily.”  Thus THCA-B is the molecule used in computer modeling studies of cannabinoid receptors. Chemical Structures (from left) of THC, THCA-A, and THCA-B Researchers investigating THCA’s mechanism of action are confounded by how readily it transforms into neutral THC by loss of a carboxyl group (COOH). This decarboxylation occurs not just when THCA is smoked or baked,  but even at room temperature. McPartland et al report that the THCA-A standard provided them by Cayman Chemical —supposedly 100% pure— turned out to be 2% THC. McPartland et al disagree with Dr. Guillermo Moreno-Sanz, a researcher at UC Irvine School of Medicine, who contends that THCA-A  is non-psychoactive because it cannot cross the blood-brain barrier. Moreno-Sanz concluded in a paper wittily entitled “Can you pass the acid test?” (and in a talk to the Society of Cannabis Clinicians)...

Read More

Defending the CUD Diagnosis

From Dr. Jordan Tishler re: “A ‘Severe’ Case of Cannabis Use Disorder” While the DSM-V is clearly overly vague about the criteria for CUD, and the authors also do derive income from treating CUD, this patient also clearly has a problem.  He clearly wants to cut down but can’t, he’s having conflict in his primary relationships, potentially spending money he can’t afford, and is missing his obligations as a result of use. To assert that anyone treating CUD is suspect makes us suspect as clinicians treating people with Cannabis.  We all derive income from treating patients. Further, to assert...

Read More

Towards a Protocol for Treating Glioblastoma

A poster at the recent ICRS meeting —Case Report: Clinical Outcome and Image Response of Two Patients After Chemoradiation Treatment in Association With CBD— gave Joe D. Goldstrich, MD, some confirmation for the protocol he has been using for glioblastoma patients. Here is the poster by Paula B. Dall’Stella, Marcos F. L. Docema, Marcos V. C. Maldaun, Olavo Feher and Carmen L. P. Lancellotti. The authors are in the Department of Neuro-Oncology, Sirio Libanes Hospital, São Paulo, SP, Brazil. Gliomas, the most common primary brain tumors, account for more than 40% of all CNS neoplasms and are highly resistant to the...

Read More

The DIS-implementation of Prop 215

Numerous government agencies have been working hard to implement California’s “legalization” law that takes effect next year. Contrast the bureaucats’ activity with their response to California voters passing legalizing cannabis for medical use, when they did less than zero. Passing an initiative is only half the battle, it turned out. Implementation is everything. In 1996, California’s top Law Enforcers actually tried to get Prop 215 overridden by the feds. As journalist Pat McCartney wrote in O’Shaughnessy’s, “Documents obtained by this reporter from state and local agencies, and litigants in the Conant v. McCaffrey case, reveal California officials committing acts...

Read More

CBD promotes cardiovascular health

Saorise O’Sullivan, PhD, summarized the extremely promising results of her research at this year’s meeting of the International Cannabinoid Research Society in Montreal. O’Sullivan is Associate Proferssor on the Faculty of Medicine and Health Sciences at the University of Nottingham.  Her talk on “Cardiovascular Effects of Cannabinoids” won the ICRS’s Young Investigator Award. Here’s the abstract: Cannabidiol (CBD) is a non-psychoactive phytocannabinoid already on the market as part of a licensed treatment in multiple sclerosis (Sativex® GW Pharmaceuticals, Cambridge, UK). CBD alone (Epidiolex®, GW Pharmaceuticals, Cambridge, UK) is also in clinical trials in children with intractable epilepsies and has...

Read More

RCT confirms that cannabinoids help adults with ADHD

 “Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial,” by R.E. Cooper and colleagues at Kings College London has been e-published in European Neuropsychopharmacology. “Adults with ADHD may represent a subgroup of individuals who experience a reduction of symptoms and no cognitive impairments following cannabinoid use,” the abstract concludes. “While not definitive, this study provides preliminary evidence supporting the self-medication theory of cannabis use in ADHD.” (Thanks to Joe. D. Golstrich, MD, for forwarding.) The trial by Cooper et al was conducted with Sativex, GW’s Oromucosal Spray, which contains a 50-5o mix of THC and CBD. The peer-reviewed results confer credibility on the thousands of...

Read More

A ‘Severe’ Case of Cannabis Use Disorder

  Picture a gigantic, inverted pyramid resting on a wee, small point. The apex has become the base.    Cannabis Prohibition —which generates billions of US dollars for therapists, law enforcers, and bureaucrats— now depends almost entirely on the existence of “Cannabis Use Disorders” as defined by the American Psychiatric Association. No longer can the “experts” claim that smoking marijuana causes lung cancer and COPD (thanks to the very thorough clinical trial led by UCLA’s Donald Tashkin, MD).  The actual pulmonary insult is Bronchitis, which disappears within weeks when one stops smoking.   In the latest version of the...

Read More

Chronicling ‘Legalization’

A note (below) from David Downs, Cannabis Editor of the San Francisco Chronicle, reminds us that Tod Mikuriya, MD, tried in vain after Prop 215 passed in 1996 to get support for an “audit” (Tod’s term) that would have pressured state and county agencies to adjust their policies in accordance with the new law. The victory of Prop 215 had come as a stunning surprise —and a clear rebuke— to California politicos and bureaucrats. They were momentarily back on their heels, and Tod knew how important it was to keep the political momentum. Winning the election —creating a new...

Read More

The Treatment Racket Needs Cleaning Up

The cruel corruption of the Drug Treatment Racket is described by Lizette Alvarez of the New York Times in a piece focused on Delray Beach, Florida. An accompanying photo by Scott McIntyre shows young white cops and paramedics treating a young white man empathetically as he emerges from an overdose. It’s exactly how all citizens should be treated.  In the period ahead, Cannabis will be incorporated into Recovery protocols —a strategy advocated by Tod Mikuriya, MD, more than 20 years ago. And “Harm Reduction” will enter the lingo, just like “CBD” and “terpenes.”  Cassandra sez she’s sure of it. ...

Read More